Chimeric Antigen Receptor T-Cell Therapy | Oncology Grand Rounds Series: Part 11 — Chimeric Antigen Receptor T-Cell Therapy

published 1 month ago by Dr Neil Love

Proceedings from the last in a series of 11 integrated webinars held in association with the 2021 ONS Annual Congress. Featuring perspectives from Drs Jeremy Abramson, Caron Jacobson and Noopur Raje on cases from the practices of Ms Sonia Glennie, Alli McClanahan and Ms Elizabeth Zerante, including the following topics: Introduction (0:00) CD19-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy in Chronic Lymphocytic Leukemia (CLL) and Lymphomas (4:07) Case: A man in his mid-60s with relapsed diffuse large B-cell lymphoma (DLBCL) who received axicabtagene ciloleucel — Sonia Glennie, ARNP, MSN, OCN (5:09) Case: A woman in her early 60s with relapsed CLL who received lisocabtagene maraleucel — Elizabeth Zerante, MS, AGACNP-BC (25:35) Case: A man in his early 60s from the Netherlands with high-grade DLBCL who received axicabtagene ciloleucel — Alli McClanahan, MSN, APRN, ANP-BC (33:28) COVID-19, CAR T-Cell Therapy and Clinical Oncology (47:17) B-Cell Maturation Antigen (BCMA)-Targeted CAR T-Cell Therapy in Multiple Myeloma (1:01:33) Case: A man in his late 60s who received BCMA-targeted CAR T-cell therapy bb21217 – Ms McClanahan (1:08:49) Case: A man in his mid-60s who received BCMA-targeted CAR T-cell therapy bb21217 during the COVID-19 pandemic — Ms McClanahan (1:15:13) The Challenges of Oncology and Hope for the Future: “What Is to Give Light Must Endure the Burning” (1:23:00) NCPD information and select publications

more episodes from Research To Practice | Oncology Videos